Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma - The DD protocol

Página do item simplificado
dc.contributor.authorDulley, Frederico Luiz
dc.contributor.authorSaboya, Rosaura
dc.contributor.authorde Moraes Hungria, Vãnia Tietsche
dc.contributor.authorBueno, Nadjanara Dorna
dc.contributor.authorde Mello, Fernando Gomes [UNESP]
dc.contributor.authorFrota, Maria Tereza
dc.contributor.authorChiattone, Carlos Sergio
dc.contributor.authorBarros, José Carlos
dc.contributor.authorMori, Nair Sumie
dc.contributor.authorSturaro, Daniel
dc.contributor.authorde Almeida Macedo, Maria Cristina Martins
dc.contributor.authorda Silva, Roberto Luiz
dc.contributor.authorde Melo, Leila Maria Magalhães Pessoa
dc.contributor.authorSouza, Cármino Antonio
dc.contributor.institutionHospital Sírio-Libanês
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionFaculdade de Ciências Médicas da Santa Casa de São Paulo
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionFaculdade de Medicina de Taubaté
dc.contributor.institutionSanta Casa Hospital
dc.contributor.institutionAv. Dr. Eneas Carvalho Aguiar 155
dc.date.accessioned2014-05-27T11:21:40Z
dc.date.available2014-05-27T11:21:40Z
dc.date.issued2005-11-01
dc.description.abstractContext and Objective: Lipasomial daunorubicin has been used to treat hematological malignancies, including multiple myelomo (MM). The goal was to evaluate efficacy, side-effects and toxicity of liposomal daunorubicin and dexamethasone (DD Protocol). Design and Setting: Prospective study of Sírio-Libonês, São Camilo, Brasil and Alemão Oswaldo Cruz hospitals. Methods: Twenty consecutive patients with active MM received four cycles of liposomal daunorubicin intravenously for two hours (25-30 mg/m 2/day) on three consecutive days per month, with oral dexamethasone, (10 mg every six hours) on four consecutive days three times a month. Results: The male/female ratio was 1:1 and median age 60. Nine patients were stage IIA, ten IIIA and one IIIB. The median from diagnosis to starting DD was 13 months. All patients received four cycles, except one. Fifteen had already received chemotherapy before DD. Responses of > 50% reduction in serum monoclonal paraprotein were observed in six patients after first cycle (30%), six after second (30%) and four after third (20%), while four (20%) did not obtain this. Initially, 17 patients (85%) had anemia: 12 (70%) achieved correction. Progressive disease was observed in three patients (15%), while one had minimal response, four (20%) partial and 12 (60%) complete. Hemotologlical toxicity was acceptable: three patients (15%) had neutrophils < 1,000/mm 3; none had thrombocyfopenia. Gastrointestinal toxicity was mild: nausea (10%), anorexio (15%) and no vomiting. Conclusions: This treatment has mild toxicity and good response rate. It may therefore be feasible before autologous bone marraw transplantation.en
dc.description.affiliationHospital Sírio-Libanês, São Paulo
dc.description.affiliationFaculdade de Medicina Universidade de São Paulo, São Paulo
dc.description.affiliationBone Marrow Transplant Unit Hospital das Clínicas Universidade de São Paulo, São Paulo
dc.description.affiliationDepartment of Hematology Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo
dc.description.affiliationDepartament of Hematology Faculdade de Medicina Universidade de São Paulo, São Paulo
dc.description.affiliationDepartment of Hematology Faculdade de Medicina de Botucatu, São Paulo
dc.description.affiliationDepartment of Hematology Faculdade de Medicina de Taubaté, Taubaté, São Paulo
dc.description.affiliationBone Marrow Transplant Unit Santa Casa Hospital, São Paulo
dc.description.affiliationDepartment of Hematology Hospital das Clínicas Universidade de São Paulo, São Paulo
dc.description.affiliationServiço de Transplante de Medula Óssea Av. Dr. Eneas Carvalho Aguiar 155, São Paulo, SP 05403-000
dc.description.affiliationUnespDepartment of Hematology Faculdade de Medicina de Botucatu, São Paulo
dc.format.extent266-270
dc.identifierhttp://dx.doi.org/10.1590/S1516-31802005000600003
dc.identifier.citationSao Paulo Medical Journal, v. 123, n. 6, p. 266-270, 2005.
dc.identifier.doi10.1590/S1516-31802005000600003
dc.identifier.file2-s2.0-33750046937.pdf
dc.identifier.issn1516-3180
dc.identifier.scieloS1516-31802005000600003
dc.identifier.scopus2-s2.0-33750046937
dc.identifier.urihttp://hdl.handle.net/11449/68477
dc.language.isoeng
dc.relation.ispartofSão Paulo Medical Journal
dc.relation.ispartofjcr1.063
dc.relation.ispartofsjr0,334
dc.rights.accessRightsAcesso aberto
dc.sourceScopus
dc.subjectDaunorubicin
dc.subjectDexamethasone
dc.subjectDrug theraphy
dc.subjectDrug toxicity
dc.subjectMultiple myeloma
dc.subjectbleomycin
dc.subjectcyclophosphamide
dc.subjectdaunorubicin
dc.subjectdexamethasone
dc.subjectdoxorubicin
dc.subjectliposome
dc.subjectmelphalan
dc.subjectparaprotein
dc.subjectprednisone
dc.subjectvincristine
dc.subjectadult
dc.subjectaged
dc.subjectalopecia
dc.subjectanemia
dc.subjectanorexia
dc.subjectasthenia
dc.subjectautologous bone marrow transplantation
dc.subjectBrazil
dc.subjectcancer combination chemotherapy
dc.subjectcancer growth
dc.subjectcancer staging
dc.subjectcardiotoxicity
dc.subjectclinical article
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdose response
dc.subjectdrug efficacy
dc.subjectdrug fatality
dc.subjectdrug response
dc.subjectdrug safety
dc.subjectfeasibility study
dc.subjectfemale
dc.subjectgastrointestinal symptom
dc.subjecthematologic malignancy
dc.subjecthuman
dc.subjectmale
dc.subjectmultiple myeloma
dc.subjectnausea
dc.subjectneutropenia
dc.subjectpneumonia
dc.subjectprospective study
dc.subjectprotein blood level
dc.subjectthrombocytopenia
dc.subjecturinary tract infection
dc.subjectvomiting
dc.subjectAdult
dc.subjectAged
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectDrug Administration Schedule
dc.subjectFemale
dc.subjectHumans
dc.subjectLiposomes
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMultiple Myeloma
dc.subjectParaproteins
dc.subjectProspective Studies
dc.subjectTreatment Outcome
dc.titleLiposomal daunorubicin and dexamethasone as a treatment for multiple myeloma - The DD protocolen
dc.typeArtigo
dcterms.licensehttp://www.scielo.br/revistas/spmj/paboutj.htm#03
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatupt

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
2-s2.0-33750046937.pdf
Tamanho:
145.73 KB
Formato:
Adobe Portable Document Format
Baixar

Coleções

Artigos - Clínica Médica - FMB